Application Note: In vivo safety and efficacy platform for immunotherapies
5 April 2024

The Cytokine Release Syndrome (CRS) Studies from JAX are the only in vivo platform to assess the efficacy and safety of therapeutic agents, such as bispecific antibodies and chimeric antigen receptor T cells (CAR Ts). The Jackson Laboratory gives an overview of its PBMC Humanized Mice Based Platform, a novel assay that provides holistic toxicity and efficacy data, reveals multi-tissue and multi-organ responses, and enables a more accurate assessment of cytokine release. Donor-specific differences mimic the human pathophysiology in diverse populations and ultimately help de-risk the preclinical drug development pipeline.